{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:22:53Z","timestamp":1784859773367,"version":"3.55.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patient-reported outcomes (PROs) are associated with treatment outcomes in multiple myeloma (MM) in the clinical trial setting. However, most PRO tools are time consuming, which hinders use in routine practice. Our institution incorporated a \u201cHematology Patient-Reported Symptom Screen\u201d (HPRSS), a 3-item questionnaire for fatigue, pain, and quality of life (QOL). The main objective of this study was to evaluate the impact of these symptoms on progression-free survival (PFS) and overall survival (OS) in a real-world cohort of patients with newly diagnosed MM. This retrospective study included patients with MM diagnosed between April 2011 and December 2017, seen at Mayo Clinic (Rochester, MN), who completed the HPRSS. Patients rated their symptoms on a scale from 0 to 10. Clinically relevant symptoms were defined as scores \u22655 for pain and fatigue, and \u22645 for QOL. At diagnosis, 735 patients had scores for all domains. The median follow-up was 8.1 years. Age was associated with increased odds of fatigue and decreased QOL. Female sex and comorbidities were associated with fatigue and pain. Higher disease stage, anemia, lytic lesions, and increased plasma cell burden were associated with fatigue, pain, and decreased QOL. Clinically relevant fatigue, pain, and decreased QOL were associated with decreased PFS and OS. On multivariate analysis including age, International Staging System III, high-risk cytogenetics, and postinduction transplantation, fatigue and decreased QOL were independently associated with decreased OS. A composite HPRSS score stratified patients into 3 groups with distinct OS. Patient-reported symptoms are prognostic in patients with newly diagnosed MM. The prognostic values of fatigue and decreased QOL are independent of age, disease stage, and transplant status.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024014232","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:02:52Z","timestamp":1733428972000},"page":"884-892","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Prognostic impact of patient-reported symptoms in multiple myeloma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"first","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Bohra","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7742-734X","authenticated-orcid":false,"given":"Aytaj","family":"Mammadzadeh","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie","family":"Gertz","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"ElHaj","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-0326","authenticated-orcid":false,"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3095-2590","authenticated-orcid":false,"given":"Terri","family":"Menser","sequence":"additional","affiliation":[{"name":"2Division of Health Care Delivery Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"issue":"5","key":"2025032418272188200_bib1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"2025032418272188200_bib2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"5","key":"2025032418272188200_bib3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"issue":"8","key":"2025032418272188200_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.6004\/jnccn.2020.7561","article-title":"Symptom burden, perceived control, and quality of life among patients living with multiple myeloma","volume":"18","author":"Zaleta","year":"2020","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"2025032418272188200_bib5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.annemergmed.2012.10.010","article-title":"Do patient-reported symptoms predict emergency department visits in cancer patients? A population-based analysis","volume":"61","author":"Barbera","year":"2013","journal-title":"Ann Emerg Med"},{"issue":"suppl 1","key":"2025032418272188200_bib6","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1182\/blood-2021-146862","article-title":"Is symptom burden associated with health care utilization: a longitudinal population-based cohort study of transplant ineligible patients with newly diagnosed multiple myeloma","volume":"138","author":"Mian","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2025032418272188200_bib7","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1111\/jgs.15045","article-title":"High symptom burden and low functional status in the setting of multimorbidity","volume":"65","author":"Portz","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"issue":"5","key":"2025032418272188200_bib8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0269216319833588","article-title":"Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study","volume":"33","author":"Ramsenthaler","year":"2019","journal-title":"Palliat Med"},{"issue":"suppl 1","key":"2025032418272188200_bib9","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1182\/blood-2021-148191","article-title":"Lenalidomide dosing and outcomes in transplant-ineligible patients with newly-diagnosed multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) database","volume":"138","author":"Mian","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2025032418272188200_bib10","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1002\/cam4.5245","article-title":"Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: results from the Canadian Myeloma Research Group database","volume":"12","author":"Mian","year":"2023","journal-title":"Cancer Med"},{"issue":"8","key":"2025032418272188200_bib11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00277-020-04023-4","article-title":"The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma","volume":"99","author":"Merz","year":"2020","journal-title":"Ann Hematol"},{"issue":"8","key":"2025032418272188200_bib12","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2025032418272188200_bib13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.2022.11238","article-title":"Patient-reported outcome measures in clinical research","volume":"328","author":"Weinfurt","year":"2022","journal-title":"JAMA"},{"issue":"23","key":"2025032418272188200_bib14","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.3390\/cancers14236007","article-title":"The reporting, use, and validity of patient-reported outcomes in multiple myeloma in clinical trials: a systematic literature review","volume":"14","author":"Salek","year":"2022","journal-title":"Cancers"},{"issue":"7","key":"2025032418272188200_bib15","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clml.2022.01.009","article-title":"Patient-reported outcomes in randomized controlled trials of patients with multiple myeloma: a systematic literature review of studies published between 2014 and 2021","volume":"22","author":"Efficace","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"38","key":"2025032418272188200_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/EDBK_200383","article-title":"Implementation of patient-reported outcomes in routine medical care","volume":"38","author":"Basch","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"2025032418272188200_bib17","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ajh.24676","article-title":"Hematology patient reported symptom screen to assess quality of life for AL amyloidosis","volume":"92","author":"Warsame","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2025032418272188200_bib18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12955-014-0187-z","article-title":"Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales","volume":"12","author":"Singh","year":"2014","journal-title":"Health Qual Life Outcomes"},{"issue":"15","key":"2025032418272188200_bib19","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International Staging System for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2025032418272188200_bib20","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2025032418272188200_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-022-00611-x","article-title":"A\u00a0simple additive staging system for newly diagnosed multiple myeloma","volume":"12","author":"Abdallah","year":"2022","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025032418272188200_bib22","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"2025032418272188200_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"issue":"2","key":"2025032418272188200_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","article-title":"Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"2025032418272188200_bib25","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","article-title":"Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes","volume":"17","author":"Shah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2025032418272188200_bib26","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood-2019-125749","article-title":"Real-world (RW) multiple myeloma (MM) patients (Pts) remain under-represented in clinical trials based on standard laboratory parameters and baseline characteristics: analysis of over 3,000 Pts from the insight MM global, prospective, observational study","volume":"134","author":"Hungria","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2025032418272188200_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jpainsymman.2023.01.020","article-title":"Prevalence, severity, and co-occurrence of SPPADE symptoms in 31,866 patients with cancer","volume":"65","author":"Kroenke","year":"2023","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"6","key":"2025032418272188200_bib28","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1007\/s00520-020-05827-w","article-title":"Symptom burden in patients with common cancers near end-of-life and its associations with clinical characteristics: a real-world study","volume":"29","author":"Batra","year":"2021","journal-title":"Support Care Cancer"},{"issue":"suppl 15","key":"2025032418272188200_bib29","doi-asserted-by":"crossref","first-page":"e18127","DOI":"10.1200\/JCO.2016.34.15_suppl.e18127","article-title":"Patient-reported symptom burden in relapsed or refractory multiple myeloma","volume":"34","author":"Williams","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2025032418272188200_bib30","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2017.76.0876","article-title":"Symptom burden in the first year after cancer diagnosis: an analysis of patient-reported outcomes","volume":"36","author":"Bubis","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"2025032418272188200_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jncimonographs\/lgh024","article-title":"Gender differences in pain, fatigue, and depression in patients with cancer","volume":"2004","author":"Miaskowski","year":"2004","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"issue":"7","key":"2025032418272188200_bib32","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3324\/haematol.2020.267757","article-title":"Symptom burden in transplant-ineligible patients with newly diagnosed multiple myeloma: a population-based cohort study","volume":"106","author":"Mian","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025032418272188200_bib33","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-014-2264-0","article-title":"Elderly multiple myeloma patients experience less deterioration in health-related quality of life than younger patients compared to a normative population: a study from the population-based PROFILES registry","volume":"94","author":"van der Poel","year":"2015","journal-title":"Ann Hematol"},{"issue":"8","key":"2025032418272188200_bib34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2025032418272188200_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-021-00602-4","article-title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"4","key":"2025032418272188200_bib36","doi-asserted-by":"crossref","first-page":"e722","DOI":"10.1634\/theoncologist.2019-0348","article-title":"The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the \u201creal-world\u201d: results from the population-based PROFILES registry","volume":"25","author":"Husson","year":"2020","journal-title":"Oncol"},{"issue":"3","key":"2025032418272188200_bib37","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/j.clml.2020.11.021","article-title":"Prevalence and survival impact of self-reported symptom and psychological distress among patients with multiple myeloma","volume":"21","author":"Richter","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2025032418272188200_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10552-020-01305-0","article-title":"Self-reported health and survival in older patients diagnosed with multiple myeloma","volume":"31","author":"Nabulsi","year":"2020","journal-title":"Cancer Causes Control"},{"key":"2025032418272188200_bib39","first-page":"1693","article-title":"Symptom burden in patients with newly diagnosed multiple myeloma","volume":"419780","author":"Abdallah","year":"2024","journal-title":"EHA Library"},{"issue":"1","key":"2025032418272188200_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A\u00a0systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025032418272188200_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"14","key":"2025032418272188200_bib42","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1200\/JCO.2013.53.5948","article-title":"What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials","volume":"32","author":"Kotronoulas","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2025032418272188200_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/884\/2356021\/blooda_adv-2024-014232-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/884\/2356021\/blooda_adv-2024-014232-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T20:08:00Z","timestamp":1742846880000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/884\/534345\/Prognostic-impact-of-patient-reported-symptoms-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024014232","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}